Patient Preferences for topical Psoriasis treatments

• Conditions: L40.0; Psoriasis vulgaris

• Registration Number: DRKS00027846
• Lead Sponsor: Klinik für Dermatologie Universitätsmedizin Mannheim

Brief Summary

The study cohort (N = 184) considered probabilities of 50% (Relative Importance Score (RIS)=41.0) and 90% (RIS = 33.9) improvement most important, followed by risk of skin atrophy (RIS = 26.4) and treatment cost (RIS = 22.2). Treatment location (RIS = 18.9), risk of skin irritation (RIS = 16.2), treatment frequency (RIS = 13.3) and formulation (RIS = 11.0) were considered less relevant. Income, cardiovascular disease, number of visits and current topical therapy influenced treatment preferences.

Detailed Description

Not available

Study Timeline

• Study Completion: 2017-09-30
• Study Start: 2022-01-20
• Results First Posted: 2022-04-04
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 198

Inclusion Criteria

physician-confirmed diagnosis of plaque-type psoriasis
written informed consent, sufficient language skills and the ability to understand the study task

Exclusion Criteria

age < 18 years

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The aim of the present study is to use a computer-based conjoint analysis to record the preferences of psoriasis patients with regard to topical therapy. The preferences are measured using the relative importance of the attributes (Relative Importance Scores= RIS) at the end of the survey for each participant .

Secondary Outcome Measures

Name	Time	Method
Characteristics that influence RIS